Novavax (NVAX) Profit After Tax: 2009-2025
Historic Profit After Tax for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to -$202.4 million.
- Novavax's Profit After Tax fell 66.84% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 219.97%. This contributed to the annual value of -$187.5 million for FY2024, which is 65.60% up from last year.
- According to the latest figures from Q3 2025, Novavax's Profit After Tax is -$202.4 million, which was down 290.01% from $106.5 million recorded in Q2 2025.
- Novavax's 5-year Profit After Tax high stood at $518.6 million for Q1 2025, and its period low was -$846.3 million during Q4 2021.
- Over the past 3 years, Novavax's median Profit After Tax value was -$121.3 million (recorded in 2024), while the average stood at -$28.2 million.
- Its Profit After Tax has fluctuated over the past 5 years, first slumped by 1,910.83% in 2021, then skyrocketed by 451.51% in 2025.
- Quarterly analysis of 5 years shows Novavax's Profit After Tax stood at -$846.3 million in 2021, then soared by 78.46% to -$182.2 million in 2022, then rose by 2.12% to -$178.4 million in 2023, then spiked by 54.58% to -$81.0 million in 2024, then slumped by 66.84% to -$202.4 million in 2025.
- Its Profit After Tax stands at -$202.4 million for Q3 2025, versus $106.5 million for Q2 2025 and $518.6 million for Q1 2025.